COVID, Volume 4, Issue 5 (May 2024) – 5 articles

Coronavirus disease-19 (COVID-19) has disproportionately affected certain demographics in England, exacerbating existing health disparities. Effective therapeutics are a critical line of defence against COVID-19, particularly for patients at elevated risk for severe disease. Surveillance systems were established to monitor the usage of COVID-19 therapeutics in hospital and community settings and to inform stewardship. Three antiviral therapies—nirmatrelvir plus ritonavir (Paxlovid^®), remdesivir (Veklury^®), and molnupiravir (Lagevrio^®)—and two neutralising monoclonal antibody therapies (nMAbs)—sotrovimab (Xevudy^®) and casirivimab with imdevimab (Ronapreve^®)—were in use in England between July 2020 and April 2023. This paper aims to illuminate trends in the utilisation of COVID-19 therapeutics treatment in both hospital and community settings, stratified by the Index of Multiple Deprivation (IMD) in England. Chapter 3 of the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report 2022 to 2023 also discusses the epidemiological surveillance of these five directly acting antiviral COVID-19 therapeutics’ use in England between 2022 and 2023. Full article

Background: Pulmonary superinfections with Herpesviridae and Aspergillus spp. are common in severe coronavirus disease 2019 (COVID-19) pneumonia but their epidemiology and impact remain poorly understood. Methods: We conducted a retrospective observational study of 61 mechanically ventilated COVID-19 patients at Deventer Hospital’s ICU (2020–2021) who underwent bronchoalveolar lavage (BL) due to clinical deterioration. We analyzed blood and respiratory samples, treatment, and clinical outcomes. Results: Among 61 mechanically ventilated COVID-19 patients who underwent BL, 34 (55.7%) had superinfections, with 18 having COVID-19-associated pulmonary aspergillosis (CAPA), 7 having herpes simplex virus (HSV) infection, and 9 having both. Patients with HSV had later diagnoses (median 14 vs. 8 days, p = 0.014), longer mechanical ventilation (median 47 vs. 18.5 days, p = 0.015), and longer ICU stays (median 74 vs. 24 days, p = 0.021) compared to CAPA patients. At baseline, laboratory parameters and treatment (dexamethasone or tocilizumab) showed no significant association with superinfections. Mortality did not differ significantly among groups. Conclusion: In mechanically ventilated COVID-19 patients undergoing bronchoalveolar lavage, HSV reactivation occurred later in the course of illness and was associated with longer mechanical ventilation and ICU stays compared to CAPA. Baseline parameters did not predict superinfections. Full article

Amid the backdrop of the COVID-19 pandemic, the living conditions of the population were dramatically altered, with social distancing measures and the looming threat to public health leaving a profound impact on people’s lives. This study aims to assess the influence of COVID-19 on subjective well-being and overall quality of life in Mexico. A structural model with latent variables was used. Data were extracted from the National Self-Reported Well-being Survey (SWLS) from October 2020 and January 2021, featuring a robust sample size of 3615 residents from urban areas in Mexico, all aged 18 and above. Findings revealed that around 38% of the variance in overall life satisfaction in October 2020 and January 2021 could be attributed to Personal well-being (0.231), Personal satisfaction (0.320), Satisfaction with the environment (0.076), and Negative emotional states (−0.116). In comparison, October 2019 to January 2020 saw a lower 20% explained variance, primarily associated with Personal well-being (0.184), Personal satisfaction (0.270), and Satisfaction with the environment (0.052). Reliability assessments, including Cronbach’s Alpha coefficients, Rho_a, and Composite Reliability, all surpassed 0.70 for each subscale. In addition, our study confirmed convergent validity, as the Average Variance Extracted (AVE) consistently exceeded 0.50 across all subscales, while the discriminant coefficient exceeded 0.70. Full article

Background: The outbreak of the COVID-19 pandemic has caused an unprecedented and unexpected change all around the globe. The long-term effects are still ongoing, especially those related to the confinement measures. The study took place during the first COVID-19 lockdown in Italy, where everyone was forced to stay home in order to reduce the spread of the virus. The aim was to investigate the role of perceived emotional intelligence abilities (PEI) in coping with COVID-19-related anxiety. Methods: A cross-sectional study design was employed, and this study used an online survey launched through social networks, inviting adults to participate. The participants anonymously completed a three-scale online measurement of self-reported emotional abilities, coping strategies (approach and avoidance), and state anxiety towards COVID-19. Results: perceived emotional intelligence and approach coping significantly predicted state anxiety. In addition, perceived emotional intelligence mediated the relationship between approach coping and state anxiety. Conclusions: the study highlights the positive role of perceived emotional abilities in dealing with the unprecedented event represented by the COVID-19 pandemic, and in particular, in coping with anxiety related to lockdown and confinement. Their results highlight the importance of fostering emotional intelligence for navigating critical life events. Full article

This article focuses on individuals with Long COVID after contracting SARS-CoV-2. Although some patients have complications such as diabetes mellitus or tissue damage to the heart or lungs as a result of SARS-CoV-2 infection, our research focuses on individuals who have persistent symptoms that are not consistent with major organ dysfunction. The current article reviews methodological and conceptual issues that need to be considered in the development and use of a case definition for Long COVID and discusses the significance of appropriately phrasing questions assessing symptoms, specifying thresholds for when to count a symptom, determining how many symptoms should be required for a diagnosis, assessing symptoms over time, using multiple assessment modalities, and differentiating symptomatology from functionality. Dealing with these issues, particularly triangulating data from multiple sources, allows investigators to develop a more reliable and valid way to assess Long COVID. Full article